Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Alyftrek in cystic fibrosis patients aged 1 year and older
2022-503081-74-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label trial of adapalene + clindamycin, vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Planned start Sep 2023; status: authorised.
02
Drugs
adapalene + clindamycinvanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2022-503081-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503081-74-00.